Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study.
Anxious J NiwahaLauren R RodgersAlice L J CarrPriscilla A BalungiRaymond MwebazeAndrew T HattersleyBeverley M ShieldsMoffat J NyirendaAngus G JonesPublished in: BMJ open diabetes research & care (2022)
In a low-resource sub-Saharan African setting, hypoglycemia is infrequent among people with type 2 diabetes receiving sulphonylurea treatment, and the modest excess occurs predominantly in those with tight glycemic control.